Literature DB >> 31063078

Should female sex workers be offered HPV vaccination?

Maarten F Schim van der Loeff1,2,3, Alex Vorsters4, Elske Marra1, Pierre Van Damme4, Arjan Hogewoning1,5.   

Abstract

Prophylactic vaccines are efficacious in preventing Human Papillomavirus (HPV) infection and subsequent cervical intraepithelial neoplasia (CIN), cervical cancer, other anogenital cancers, and anogenital warts. Female sex workers (SW) are at increased risk of acquiring sexually transmitted infections, including HPV. There are several reasons to offer HPV vaccination to SW: they are at high risk for HPV and often unvaccinated, and the immunogenicity of the vaccine is also excellent in previously HPV exposed women. Furthermore, women with disease caused by HPV may still benefit from vaccination. The efficacy of vaccinating mid-adult women (26-44 years old) against persistent HPV infection and CIN2+ is good. Although an SW may have been infected or exposed to HPV, she may not have been exposed to all vaccine-included hrHPV types. Vaccination induces mucosal immunity via the production of neutralizing antibodies on the surface of the female genital tract, thus preventing potential transmission to clients. Nevertheless, some considerations argue against offering vaccination to SWs. Current vaccines are only prophylactic and as such, do not affect current HPV infections. Women who have previously cleared HPV infections, may do so again and thus not need vaccination. Fewer SW might be naïve to HPV-types than currently thought. HPV vaccination has probably no effect on latent infections. Vaccinating sometime after sexual debut could be too late, as infections have already occurred. Taken together, some data suggest that vaccination of SW may offer health benefits, also for the community, but sufficient evidence is lacking. In certain cases, HPV vaccination of SW may be recommended. Evidence-based, public health decisions concerning vaccination of SW are challenging and could be facilitated with more research in this high-risk group.

Entities:  

Keywords:  Human Papillomavirus; effectiveness; sex worker; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31063078      PMCID: PMC6746505          DOI: 10.1080/21645515.2019.1602432

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  44 in total

1.  Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

Authors:  Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

2.  High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.

Authors:  Ross D Cranston; Michelle S Cespedes; Pawel Paczuski; Ming Yang; Robert W Coombs; Joan Dragavon; Alfred Saah; Catherine Godfrey; Jennifer Y Webster-Cyriaque; Elizabeth Y Chiao; Barbara Bastow; Timothy Wilkin
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

3.  Vaginal and anal human papillomavirus infection and seropositivity among female sex workers in Amsterdam, the Netherlands: Prevalence, concordance and risk factors.

Authors:  E Marra; N Kroone; E Freriks; C L van Dam; C J Alberts; A A Hogewoning; S Bruisten; A van Dijk; M M Kroone; T Waterboer; M F Schim van der Loeff
Journal:  J Infect       Date:  2017-12-28       Impact factor: 6.072

4.  Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

Authors:  A Szarewski; W A J Poppe; S R Skinner; C M Wheeler; J Paavonen; P Naud; J Salmeron; S-N Chow; D Apter; H Kitchener; X Castellsagué; J C Teixeira; J Hedrick; U Jaisamrarn; G Limson; S Garland; B Romanowski; F Y Aoki; T F Schwarz; F X Bosch; D M Harper; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

5.  Episodic detection of human papillomavirus within a longitudinal cohort of young women.

Authors:  Marcia L Shew; Aaron C Ermel; Yan Tong; Wanzhu Tu; Brahim Qadadri; Darron R Brown
Journal:  J Med Virol       Date:  2015-06-25       Impact factor: 2.327

6.  Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV infection among South African women.

Authors:  Chunhui Wang; Thomas C Wright; Lynette Denny; Louise Kuhn
Journal:  J Infect Dis       Date:  2011-01-07       Impact factor: 5.226

Review 7.  Prevalence and genotype distribution of cervical human papillomavirus infection among female sex workers in Asia: a systematic literature review and meta-analysis.

Authors:  Rui-Rui Peng; Hong-Min Li; Helena Chang; Jian-Hong Li; Alberta L Wang; Xiang-Sheng Chen
Journal:  Sex Health       Date:  2012-05       Impact factor: 2.706

8.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

9.  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

Authors:  X Castellsagué; N Muñoz; P Pitisuttithum; D Ferris; J Monsonego; K Ault; J Luna; E Myers; S Mallary; O M Bautista; J Bryan; S Vuocolo; R M Haupt; A Saah
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

10.  The Potential Benefits of HPV Vaccination in Previously Infected Women.

Authors:  John T Schiller
Journal:  EBioMedicine       Date:  2016-08-03       Impact factor: 8.143

View more
  4 in total

1.  Letter to the editor: female sex workers and HPV vaccine.

Authors:  Brandon Brown; Alejandra Cabral
Journal:  Hum Vaccin Immunother       Date:  2019-06-28       Impact factor: 3.452

2.  Letter to the editor: female sex workers and HPV vaccine.

Authors:  Maarten F Schim van der Loeff; Alex Vorsters; Elske Marra; Pierre Van Damme; Arjan Hogewoning
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

Review 3.  There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination.

Authors:  Gregory D Zimet; Nosayaba Osazuwa-Peters
Journal:  Hum Vaccin Immunother       Date:  2019       Impact factor: 3.452

4.  Evaluating sexual health in sex workers and men who have sex with men: the SMESH cross-sectional protocol study.

Authors:  Eliana Marcia Wendland; Marina Bessel; Juliana Comerlato; Jaqueline Driemeyer Correia Horvath; Frederico Falcetta; Gerson Fernando Mendes Pereira; Flávia Moreno Alves de Souza; Carla Domingues; Ana Goretti Kalume Maranhão; Natalia Luiza Kops
Journal:  BMJ Open       Date:  2019-11-19       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.